Evidence map›Paper›PMID 32435249›Full record

ArticleFrontiers in immunology2020

Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.

Pauline Girard, Benedicte Ponsard, Julie Charles, Laurence Chaperot, Caroline Aspord

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. A GD (Gamma-Delta) type of cancel culture.Immuno-oncology technology · 2024
    Review
  6. Review
  7. The therapeutic role of γδT cells in TNBC.Frontiers in immunology · 2024
    Review
  8. T cells in health and disease.Signal transduction and targeted therapy · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Pauline GirardEtablissement Français du Sang Auvergne Rhone-Alpes, Research and Development Laboratory, Grenoble, France.
Benedicte PonsardEtablissement Français du Sang Auvergne Rhone-Alpes, Research and Development Laboratory, Grenoble, France.
Julie CharlesUniversité Grenoble Alpes, INSERM, CNRS, Team Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Grenoble, France.
Laurence ChaperotEtablissement Français du Sang Auvergne Rhone-Alpes, Research and Development Laboratory, Grenoble, France.
Caroline AspordEtablissement Français du Sang Auvergne Rhone-Alpes, Research and Development Laboratory, Grenoble, France.
Centre National de la Recherche Scientifique · FRÉtablissement Français du Sang · FRInserm · FRUniversité Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmacytoid DCs (pDCs) and γδT cells are both critical players in immunosurveillance against pathogens and cancer due to their ability to sense microbes and cell stress through recognition of pathogen-associated molecular patterns or altered metabolism [phosphoantigens (PAgs)]. Their unique features, high functional plasticity and ability to interact with many immune cell types allow them to bridge innate and adaptive immunity, initiating and orientating widely immune responses, hence contributing to protective and pathogenic immune responses. Yet, despite strategic and closed missions, potential interactions between pDCs and γδT cells are still unknown. Here we investigated whether there is interplay between pDCs and γδT cells and the underlying molecular mechanisms. Purified human pDCs and γδT cells were cocultured in presence of TLR-L, PAg, and zoledronate (Zol) to mimic both infectious and tumor settings. We demonstrated that TLR7/9L- or Zol-stimulated pDCs drive potent γδT-cell activation, Th1 cytokine secretion and cytotoxic activity. Conversely PAg-activated γδT cells trigger pDC phenotypic changes and functional activities. We provided evidence that pDCs and γδT cells cross-regulate each other through soluble factors and cell-cell contacts, especially type I/II IFNs and BTN3A. Such interplay could be modulated by blocking selective immune checkpoints. Our study highlighted crucial bidirectional interactions between these key potent immune players. The exploitation of pDC-γδT cells interplay represents a promising opportunity to design novel immunotherapeutic strategies and restore appropriate immune responses in cancers, infections and autoimmune diseases.

Indexed as

ButyrophilinsCell CommunicationCell Line, TumorDendritic CellsHumansImmunotherapyInfectionsInterferon-gammaInterferon Type INeoplasmsReceptors, Antigen, T-Cell, gamma-deltaSignal TransductionT-LymphocytesZoledronic AcidBTNL9 protein, humanButyrophilinsInterferon-gammaInterferon Type IReceptors, Antigen, T-Cell, gamma-deltaZoledronic AcidBTN3Across-talkimmune checkpointpDCsγδ T cells

Identifiers

PMID32435249
PMCPMC7218166
OpenAlexW3021955018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.